[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"chronic-bronchitis\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:chronic-bronchitis":27},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,5,0,[8,47,75,98,125],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":13,"acronym":14,"eligibilityCriteria":15,"healthyVolunteers":11,"sex":16,"minAge":4,"maxAge":17,"enrollmentInfo":18,"targetDuration":4,"studyType":21,"phases":22,"briefSummary":24,"conditions":25,"keywords":28,"overallStatus":35,"whyStopped":4,"lastUpdateSubmitDate":36,"lastUpdatePostDateStruct":37,"startDateStruct":40,"completionDateStruct":42,"leadSponsor":44,"locationsCount":4},"100628974","repeat-treatment-with-metered-cryospray-in-patients-with-chronic-obstructive-pulmonary-disease-with-chronic-bronchitis-100628974",false,"NCT07468617","Repeat Treatment With Metered Cryospray in Patients With Chronic Obstructive Pulmonary Disease With Chronic Bronchitis","MCSRETREAT","Inclusion Criteria:\n\n1. Subject has completed a previous MCS study, including both treatments (treatment day 1 and treatment day 2)\n2. Males and females \\\u003C80 years of age\n3. Subject is able to read, understand, and sign a written informed consent form in order to participate in the study\n4. Subject has a diagnosis of chronic obstructive pulmonary disease (COPD) with chronic bronchitis (CB) for a minimum of two years. (CB is defined clinically as chronic productive cough for 3 months in each of 2 successive years in a patient in whom other causes of productive cough have been excluded)\n5. Subject is classified as having a moderate or severe (GOLD 2\u002F3) airflow obstruction defined by a post-bronchodilator of \\>30% FEV1 to \\\u003C80% predicted with a baseline FEV1\u002FFVC of \\\u003C0.70\n6. Subject is being treated according to current medically accepted treatment guidelines for CB for minimum of 3 months prior to enrollment into the study.\n7. Non-smoking for a minimum of 2 months prior to consent and agrees to continue not smoking for the duration of the study\n8. Subject is able to adhere to and undergo 2 bronchoscopic procedures per hospital guidelines\n\nExclusion Criteria:\n\n1. Subject has had an acute pulmonary infection, exacerbation or pneumonia requiring medical treatment (with antibiotics and\u002For steroids) within 4 weeks prior of initially planned study bronchoscopy\n2. Subject has other origins of respiratory disease aside from CB and COPD\n3. Subject is using e-cigarettes, vaping or inhaled substances not prescribed by a physician\n4. Subject has untreatable or life-threatening arrhythmias, inability to adequately oxygenate during the bronchoscopy, or has acute respiratory failure\n5. Subject has bullous emphysema characterized as large bullae \\>30 millimeters on High Resolution Computed Tomography (HRCT); or subject has stenosis in the tracheobronchial system, tracheobronchomegaly, trachea-bronchomalacia, amyloidosis or cystic fibrosis\n6. Subject has clinically significant bronchiectasis as determined by the investigator\n7. Subject has had a solid organ transplant procedure\n8. Subject has a known mucosal tear, has undergone prior lung surgery such as pneumonectomy, lobectomy, bullectomy, or lung volume reduction surgery\n9. Subject has had a prior lung device procedure, including emphysema stent(s) implanted, lung coils, valves, lung denervation, bronchial thermoplasty, cryotherapy or other therapies\n10. Subject is unable to temporarily discontinue use of anticoagulant therapy: warfarin, Coumadin, LMWH, heparin, clopidrogel (or equal)\n11. Subject is unable to complete patient reported outcome questionnaires due to cognitive impairment, previous cerebral infarct e.g. stroke, TIA\n12. Subject has a serious medical condition, such as: uncontrolled coagulopathy or bleeding disorder, uncontrolled congestive heart failure, uncontrolled angina, myocardial infarction in the past year, renal failure, liver disease, cerebrovascular accident within the past 6 months, uncontrolled diabetes, uncontrolled hypertension or uncontrolled gastric reflux\n13. Subject is pregnant, nursing, or planning to get pregnant during study duration\n14. Subject has or is receiving chemotherapy or active radiation therapy within the past 6 months or is expected to receive chemotherapy during participation in this study\n15. Subject is or has been in another treatment study within 6 weeks of enrollment and agrees to not participate in any other treatment studies for the duration of study participation\n16. Subject has known sensitivity to medication required to perform bronchoscopy (such as lidocaine, atropine, and benzodiazepines)","ALL","80 Years",{"count":19,"type":20},10,"ESTIMATED","INTERVENTIONAL",[23],"NA","This study is being conducted to determine the safety of repeat metered cryospray (MCS) treatment in patients with COPD with chronic bronchitis previously treated with MCS.",[26,27],"COPD (Chronic Obstructive Pulmonary Disease)","Chronic Bronchitis",[29,30,27,31,32,33,34],"Chronic Obstructive Pulmonary Disease","COPD","CB","Metered Cryospray","Cryospray","RejuvenAir System","NOT_YET_RECRUITING","2026-03-16",{"date":38,"type":39},"2026-03-18","ACTUAL",{"date":41,"type":20},"2026-05-01",{"date":43,"type":20},"2027-05-01",{"name":45,"class":46},"CSA Medical, Inc.","INDUSTRY",{"id":48,"slug":49,"hasResults":11,"nctId":50,"briefTitle":51,"officialTitle":52,"acronym":4,"eligibilityCriteria":53,"healthyVolunteers":54,"sex":16,"minAge":55,"maxAge":4,"enrollmentInfo":56,"targetDuration":58,"studyType":59,"phases":4,"briefSummary":60,"conditions":61,"keywords":4,"overallStatus":63,"whyStopped":4,"lastUpdateSubmitDate":64,"lastUpdatePostDateStruct":65,"startDateStruct":67,"completionDateStruct":69,"leadSponsor":71,"locationsCount":74},"100080733","emphysema-research-registry-and-biosample-repository-100080733","NCT00307281","Emphysema Research Registry and Biosample Repository","Emphysema Research Registry; Screening Study and Genetic Testing","Inclusion Criteria:\n\n* Patients would be required to have COPD based on at least one of the following: clinical history, pulmonary function results, or radiographic results.\n\nExclusion Criteria:\n\n* none",true,"21 Years",{"count":57,"type":20},3000,"2 Years","OBSERVATIONAL","The Comprehensive Lung Center (CLC) at the University of Pittsburgh Medical Center (UPMC Health System) provides patients with any type of breathing or lung disorder a full range of diagnostic and therapeutic services. The Emphysema\u002FCOPD Research Center (ECRC) is a specialty clinic, within this center, that attempts to advance the understanding of emphysema and to evaluate new therapies for patients with emphysema. The Emphysema Research Registry will enable pulmonary research physicians to: 1) gather information and create a research registry of people who have been diagnosed with emphysema; 2) utilize this research registry with the purpose of conducting research that attempts to advance the understanding of emphysema and to evaluate new therapies; and, 3) use the research registry to identify potential candidates for future research programs. These aims will be achieved by the collection of DNA (genetic material)for analysis and storage in addition to pulmonary function tests and other medical information.",[62,29,27],"Emphysema","RECRUITING","2025-09-24",{"date":66,"type":39},"2025-09-25",{"date":68,"type":39},"2000-08",{"date":70,"type":20},"2030-07",{"name":72,"class":73},"University of Pittsburgh","OTHER",1,{"id":76,"slug":77,"hasResults":11,"nctId":78,"briefTitle":79,"officialTitle":80,"acronym":4,"eligibilityCriteria":81,"healthyVolunteers":11,"sex":16,"minAge":82,"maxAge":17,"enrollmentInfo":83,"targetDuration":4,"studyType":21,"phases":85,"briefSummary":86,"conditions":87,"keywords":4,"overallStatus":63,"whyStopped":4,"lastUpdateSubmitDate":88,"lastUpdatePostDateStruct":89,"startDateStruct":91,"completionDateStruct":93,"leadSponsor":95,"locationsCount":97},"100598203","clinical-study-of-the-pulsed-electric-field-ablation-system-in-chronic-obstructive-pulmonary-disease-100598203","NCT07068438","Clinical Study of the Pulsed Electric Field Ablation System in Chronic Obstructive Pulmonary Disease","A Clinical Evaluation of the Pulsed Electric Field Ablation System for the Treatment of the Symptoms of Chronic Bronchitis in Adult Patients With COPD","Inclusion Criteria:\n\n1. Subject's age is ≥35 years and ≤80 years.\n2. Patient has chronic bronchitis, defined as productive cough for three months in each of two successive years, whereas other causes of productive cough have been ruled out.\n3. Patient has a CAT score ≥ 10.\n4. Patient has an SGRQ score ≥ 25.\n5. Patient's responses to the first two questions of the CAT instrument sum to ≥ 7 points or the sum is 6 points and the patient's total CAT score is \\> 20 points.\n6. Patient has FEV1\u002FFVC \\\u003C 0.70.\n7. Patient has a pre-procedure post-bronchodilator FEV1 percent predicted of ≥ 30%.\n8. Patient is receiving guideline directed pharmacotherapy which includes one or more long acting bronchodilator (LAMA, LABA) with or without an inhaled corticosteroid for at least 8 weeks prior to randomization, unless the patient has attempted such therapy within the past 1 year without significant clinical response or had an adverse reaction.\n9. In the opinion of the Primary investigator, patient is able to undergo 2 bronchoscopies under general anesthesia and is able to adhere to the study follow-up schedule.\n10. Informed consent signed by the patient or legal representative.\n\nExclusion Criteria:\n\n1. Patient has known unresolved lower respiratory tract infection (e.g., pneumonia, mycobacterium avium-intracellulare infection (MAI), fungus, tuberculosis).\n2. Patient has a steroid-dependent condition requiring \\>10 mg of oral corticosteroid per day.\n3. Patient has any implantable electronic device (e.g., pacemaker, cardioverter defibrillator) that cannot be turned off during the procedure.\n4. Patient has a history of ventricular tachy-arrhythmia or clinically significant atrial tachyarrhythmia within the past two years, or sinus bradycardia with a heart rate of under than 45 beats per minute, unless the arrhythmia has been treated and\u002For patient is in regular rhythm during the screening phase.\n5. Subject has lung cancer.\n6. Patient has a pulmonary nodule or cavity that in the judgement of the Primary investigator may require intervention during the course of the study.\n7. Patient had prior lung surgery, such as lung transplant, LVRS, lobectomy, lung implant\u002Fprosthesis, metal airway stent, valves, coils or bullectomy.\n8. Patient has emphysema of greater than or equal to 50% as quantified on baseline HRCT scan as determined by the CT Core Lab.\n9. Patient has asthma based on Global Initiative for Asthma (GINA) criteria.\n10. Patient has clinically significant bronchiectasis influencing the patient's clinical symptoms of cough and phlegm.\n11. Patient has actively smoked (including tobacco, marijuana, e-cigarettes, vaping, etc.) within the last 2 months.\n12. Patient is unable to walk over 225 meters in 6 minutes.\n13. Patient has a serious medical condition that, in the Primary investigator's opinion, could compromise patient safety or confound the interpretation of the patient's response to therapy (e.g., congestive heart failure, cardiomyopathy, or myocardial infarction in the past year, renal failure, liver disease, cerebrovascular accident within the past 6 months, uncontrolled diabetes (HbA1c \\>8%), uncontrolled hypertension (diastolic BP \\>100mmHg) or autoimmune disease requiring treatment with immunosuppressant medications or a disease requiring chemotherapy).\n14. Patient has uncontrolled GERD.\n15. Patient has known severe pulmonary hypertension (pulmonary artery SP ≥ 50 mmHg).\n16. Patient has a known sensitivity to medication required to perform bronchoscopy (i.e., lidocaine, atropine, benzodiazepines).\n17. Patient is pregnant, nursing, or planning to get pregnant during study duration.\n18. Patient is currently participating in another clinical study involving an investigational product.\n19. Patient is receiving anticoagulation for a cardiovascular indication and, in the Primary investigator's opinion, unable to suspend anticoagulant medications (i.e., aspirin, clopidogrel, warfarin) during bronchoscopy in accordance.\n20. Patient has known airway colonization with drug-resistant bacteria such as Pseudomonas aeruginosa, methicillin-resistant Staphylococcus aureus, Burkholderia cepacia complex, Mycobacterium tuberculosis, Mycobacterium abscessus, Trichoderma, or other significant fungi.","35 Years",{"count":84,"type":20},210,[23],"This is a prospective, randomized, parallel group, sham-controlled, multicenter clinical trial. The objective is to evaluate the safety and effectiveness of pulsed electric field ablation system manufactured by Suzhou Hengruihongyuan Medical Technology Co., Ltd. for the treatment of the symptoms of chronic bronchitis in adult COPD patients with moderate to severe chronic bronchitis. A total of 210 patients will be randomized into the experimental group and the sham group (2:1).",[27,26],"2025-08-25",{"date":90,"type":39},"2025-09-02",{"date":92,"type":20},"2025-09-01",{"date":94,"type":20},"2027-02-01",{"name":96,"class":46},"Suzhou Hengruihongyuan Medical Technology Co. LTD",13,{"id":99,"slug":100,"hasResults":11,"nctId":101,"briefTitle":102,"officialTitle":103,"acronym":4,"eligibilityCriteria":104,"healthyVolunteers":54,"sex":16,"minAge":105,"maxAge":4,"enrollmentInfo":106,"targetDuration":4,"studyType":21,"phases":108,"briefSummary":109,"conditions":110,"keywords":112,"overallStatus":35,"whyStopped":4,"lastUpdateSubmitDate":116,"lastUpdatePostDateStruct":117,"startDateStruct":119,"completionDateStruct":121,"leadSponsor":123,"locationsCount":74},"100584586","pulmonary-deposition-of-ultrasound-rock-salt-aerosol-inhalation-therapy-100584586","NCT06891274","Pulmonary Deposition of Ultrasound Rock Salt Aerosol Inhalation Therapy","Study on the Lung Aerosol Deposition of Ultrasonic Rock Salt Inhalation Therapy","Inclusion Criteria:\n\nHealthy volunteers; Patients with chronic airway disease requiring nebulization therapy.\n\nExclusion Criteria:\n\nThose aged \\\u003C 18 years; Refusing to participate in the study; Patients requiring invasive ventilator assisted breathing; Patients with artificial airways. Patients with chronic liver and kidney function injury. Allergic to radioactive elements.","18 Years",{"count":107,"type":20},26,[23],"In the in vitro modeling phase, the investigators plan to use a realistic human upper respiratory tract model and an asymmetric ideal bronchial tree model. By combining 3D printing experiments with CFD simulations, the investigators will investigate the respiratory tract deposition rate and distribution of micro - moist particles in ultrasound rock salt aerosol inhalation therapy. This will be compared with a small - volume nebulizer to verify the effectiveness of ultrasound rock salt aerosol inhalation therapy and lay the foundation for further research on the application of this inhalation technique to other drug formulations.\n\nIn the clinical phase, the investigators plan to have subjects inhale radioactive aerosols and use PET\u002FCT imaging technology to assess the deposition rate of aerosol particles in the lungs. By quantitatively analyzing the images, the investigators will study their distribution characteristics in real human bodies to verify the accuracy of the in vitro models and the potential for clinical application.",[30,111,27],"Asthma Bronchiale",[113,114,115],"Ultrasound Rock Salt Aerosol Inhalation Therapy","Pulmonary deposition rate","small volume nebulizer","2025-03-17",{"date":118,"type":39},"2025-03-24",{"date":120,"type":20},"2025-03-31",{"date":122,"type":20},"2026-03-31",{"name":124,"class":73},"Jingen Xia",{"id":126,"slug":127,"hasResults":11,"nctId":128,"briefTitle":129,"officialTitle":129,"acronym":130,"eligibilityCriteria":131,"healthyVolunteers":54,"sex":16,"minAge":105,"maxAge":4,"enrollmentInfo":132,"targetDuration":134,"studyType":59,"phases":4,"briefSummary":135,"conditions":136,"keywords":139,"overallStatus":63,"whyStopped":4,"lastUpdateSubmitDate":144,"lastUpdatePostDateStruct":145,"startDateStruct":147,"completionDateStruct":149,"leadSponsor":151,"locationsCount":74},"100270686","copd-patient-powered-research-network-100270686","NCT02803242","COPD Patient-Powered Research Network","COPD PPRN","Inclusion Criteria:\n\n* 18 years or older that says yes to one of the following:\n* COPD diagnosis\n* Current or former smoker\n* Family history of respiratory disease\n* Symptomatic of respiratory disease\n\nExclusion Criteria:\n\n* Non-English speaking",{"count":133,"type":20},75000,"15 Years","The COPD Patient-Powered Research Network (COPD PPRN) is a patient research registry with the goal of enrolling 75,000 or more COPD patients and those at risk who are willing to share their heath information over several years and participate in research. The COPD PPRN has built an online platform to allow volunteers to enroll electronically, complete surveys, be contacted about studies they qualify for and become connected to COPD resources. The goal of the registry is to speed research to find better treatments for COPD and ultimately a cure.",[137,138,62,27],"Chronic Obstructive Pulmonary Disorder","Chronic Obstructive Lung Disease",[140,141,142,143],"copd","emphysema","bronchitis","bronchiectasis","2022-03-08",{"date":146,"type":39},"2022-03-10",{"date":148,"type":4},"2014-08",{"date":150,"type":20},"2030-01",{"name":152,"class":73},"COPD Foundation"]